

**SUPPLEMENTAL TABLE.** Univariate linear regression associations between several baseline clinical variables and VO<sub>2</sub>. ACE-I, Angiotensin-converter-enzyme inhibitor; BMI, Body mass index; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association.

	<b>Univariate analysis</b>	
	<b>B coefficient</b>	<b>P</b>
Age (years)*	-0.259	<0.001
BMI (kg/m <sup>2</sup> )*	-0.235	0.131
Atrial fibrillation/flutter*	-2.781	0.106
Diabetes mellitus*	-2.582	0.123
Hypertension*	-3.162	0.034
NYHA class*	-2.184	0.059
Creatinin (mg/dl)*	-1.228	0.135
Urea (mg/dl)*	-0.045	0.049
Hemoglobin (g/l)*	+0.642	0.137
NT-pro-BNP (1000 pg/ml)*	-0.328	0.107
TAPSE (mm)*	+1.381	0.002
Ivabradine use*	+7.933	0.001
Female sex	-2.372	0.167
Resting heart rate (beats per minute)	-0.032	0.631
Systolic blood pressure (mm Hg)	-0.041	0.349
Ischemic heart disease	+1.067	0.504
Chronic pulmonary obstructive disease	-1.484	0.698
Glucose (mg/dl)	-0.015	0.342
Sodium (mEq/l)	-0.035	0.735
Gammaglutamyl transpeptidase (u/l)	-0.011	0.197
Alanine aminotransferase (u/l)	-0.016	0.581
Bilirubin (mg/dl)	-1.419	0.409
Paced rhythm	-2.439	0.370
Cardiac resynchronization therapy	-0.401	0.901
Left ventricular ejection fraction (%)	+0.008	0.881
Left ventricular end-diastolic diameter (mm)	+0.094	0.900
Left ventricular end-systolic diameter (mm)	-0.005	0.994
Beta-blocker use	+2.223	0.406

ACE-I or ARB use	-0.140	0.981
Sacubitril-valsartan use	-2.798	0.296
Digoxin use	-1.860	0.565
Amiodarone use	-1.912	0.511
Mineralocorticoid receptor antagonist use	-0.613	0.716
Diuretic use	-2.193	0.297

\*These 12 variables entered the first step of the multivariable backward stepwise multiple linear regression analysis.